AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06121414 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Laserpuncture
Description: Sham laser using laserpuncture in off condition
Study NCT05428150 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esbriet 267 MG Oral Capsule
Description: Reference Formulation
Study NCT05428150 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EXCL-100, 600 MG Oral Tablet
Description: Test Formulation
Study NCT05642858 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital Educational Messaging
Description: Education via mobile phone text messages for up to 6 months.
Study NCT04911582 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cafestol 12 mg
Description: Capsule with 12 mg cafestol
Study NCT04911582 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule without cafestol
Study NCT04911582 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cafestol 6 mg
Description: Capsule with 6 mg cafestol
Study NCT06770725 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Temporal Adaptation Intervention
Description: The research on temporal adaptation intervention will be conducted through activities and individual sessions within the framework of temporal adaptation intervention. The activities included in the temporal adaptation intervention used in our research have been adapted for ADHD by referencing temporal adaptation training models in the literature.
Study NCT06770725 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Occupational Therapy
Description: The control group will be given a 10-week-long conventional occupational therapy intervention by the investigator (Fatma Temizkan). The intervention will consist of occupational therapy approaches such as; obstacle courses, sensory integration, motor skills training, cognitive skills training, sequenced activities and so on.
Study NCT06771609 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adebry single antibody + VEX metronomic chemotherapy + radiotherapy
Description: 1、Adebry antibody: 1200mg on day 1, every 3 weeks； 2、VEX Metronomic Chemotherapy: Vinorelbine 20mg orally, once every other day, Q3W Cyclophosphamide 50mg orally, once daily, Q3W Capecitabine 500mg orally, three times daily, Q3W
Study NCT06771609 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: debry single antibody + VEX metronomic chemotherapy
Description: 1、Adebry antibody: 1200mg on day 1, every 3 weeks； 2、VEX Metronomic Chemotherapy: Vinorelbine 20mg orally, once every other day, Q3W Cyclophosphamide 50mg orally, once daily, Q3W Capecitabine 500mg orally, three times daily, Q3W
Study NCT06772857 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin is a drug used to manage blood glucose levels. It improves insulin sensitivity and reduces glucose production in the liver. This regimen will be provided to all study groups (A, B, and C) in combination with the respective interventions described for each group. Participants are instructed not to change their physical activity during the study.
Study NCT05613530 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MAX NEONAT
Description: Participants use a digital, hand-held, cognitive aid (a mobile application named MAX NEONAT) and the ILCOR 2020 algorithm poster.~This group consists of a resident in pediatrics + 2 midwifes.
Study NCT05613530 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: standard of care
Description: no cognitive aid but poster/paper only
Study NCT05802953 — intervention group
Intervention type: OTHER
Intervention: Physical assessments
Description: Physical assessments include the presence of joint sounds (yes/no), Fonseca Anamnestic Questionnaire, tenderness/pressure pain threshold rating, muscle strengths assessments, temporomandibular joint and cervical region range of motion measurements, and pain.
Study NCT05802953 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: General Health Questionnaire-28 and SF-36 will be apply.
Study NCT06523413 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Game activity
Description: A game determined by the researcher will be played with the patients in the patient room.
Study NCT06523413 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stres Ball
Description: Patients will use the stress ball for 15 minutes.
Study NCT05536271 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bisoprolol Fumarate
Description: antihypertensive medicine prescribed for acute coronary syndrome patients
Study NCT06157788 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: functional Magnetic Resonance Imaging and clinical assessment
Description: * fMRI task: In the active condition, video cues were utilized (lasting 10s) depicting everyday activities that trigger shoulder apprehension. Control videos were created to match the previous content, except for the absence of cues inducing shoulder apprehension. Following each video, a visual analog scale appeared for a duration of 2.5s, and participant were asked to rate the level of perceived apprehension, using an MRI-compatible response box. The rating scale consisted of nine steps, ranging from no apprehension to high apprehension. After providing their rating, participants had a rest period during which a fixation cross was displayed visually for 17.5s. Apprehension and control videos were shown in a pseudo-randomized fashion.~* General Linear Model Analysis of Task-Related Activation~* TICA Analysis of Functional Connectivity~* White Matter TBSS of DTI Data~* Voxel-based morphometry analysis of T1 images
Study NCT06471764 — intervention group
Intervention type: DEVICE
Intervention: FX+ and 12-Lead ECG Recording
Description: While lying down, subjects will wear the FX+, a chest strap device which will measure cardiac electrical activity to generate a continuous heart rate measurement. Simultaneously, electrodes for the 12-Lead ECG will be placed on the chest and arms/legs to record the electrical activity. Two 30-second recordings from the FX+ will be taken simultaneously with the 12-lead ECG with no more than a 3-minute interval between the two recordings.
Study NCT04676737 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TTHX1114(NM141)
Description: TTHX1114
Study NCT05376085 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-5215 Tab
Description: single oral administration of 1 tablet of DA-5215 Tab with 150mL water
Study NCT05376085 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-5215-R Tab
Description: single oral administration of 1 tablet of DA-5215-R Tab with 150mL water
Study NCT06536400 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK42360
Description: Oral administration, QD
Study NCT05575050 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Oral Procedure
Description: Interventions included 2 variants of oral hygienic procedures. One was extended of teeth brushing.
Study NCT05366504 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: LiST + PRP intracorporeal injection
Description: 12 LiST sessions (2 sessions per week) plus PRP (2 intracorporeal injections 3 weeks apart, after the 1st and the 7th LiST sessions) ( 30 patients).
Study NCT05366504 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: LiST + Placebo(normal saline intracorporeal injection)
Description: All subjects of this group will receive 12 sessions (V3-V14) of LiST with session frequency 2/week and 2 normal saline injections with 3 weeks treatment interval (V3 and V9), 10 ml of normal saline will be injected at each session.
Study NCT06772857 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin is a drug used to manage blood glucose levels. It improves insulin sensitivity and reduces glucose production in the liver. This regimen will be provided to all study groups (A, B, and C) in combination with the respective interventions described for each group. Participants are instructed not to change their physical activity during the study.
Study NCT01184950 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trainer Curriculum
Study NCT06772584 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desmopressin Acetate 0.2 mg Tablets
Description: 3 groups of patients one received only desmopressin and group ginkobiloba ablnd group for both
Study NCT06772584 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ginkgobiloba
Description: Group s take it as treatment of deep sleep in nectornal enuresis
Study NCT05878652 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3D printed knee extender device
Description: Participants will receive the standard of prehabilitation education at Sanford as well as a 3D printed knee extension device with sealed water bottles and a home prehabilitation program designed to be used with the 3D printed knee extension device.
Study NCT05878652 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard Prehabilitation Education
Description: Participants in the control group will receive the standard prehabilitation education at Sanford and provided exercises to do at home.
Study NCT05069584 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: patient must have a biopsy for his prostate cancer
Study NCT05069584 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biopsy
Description: patient must have a biopsy for his prostate cancer
Study NCT05358379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CYC140
Description: CYC140 is a highly selective, orally- and intravenously- available, ATP-competitive inhibitor of PLK1.
Study NCT05818657 — intervention group
Intervention type: BIOLOGICAL
Intervention: levels of CKD markers, Oral health status, apical periodontitis
Description: To observe levels of CKD markers :Levels of serum keratinise ,urea, eGFR, and assessment of Oral health status, apical periodontitis
Study NCT05818657 — intervention group
Intervention type: BIOLOGICAL
Intervention: systemic inflammatory marker, Oral health status, apical periodontitis
Description: estimation of hs-CRP levels, and assessment of Oral health status, apical periodontitis
Study NCT05541536 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Consultation meeting
Description: Study team member will approach mothers \< 24 hrs (up to 5 min prior) of CRC approach for NRN trial. During the consultation meeting (5 minutes), the study team member will review the pamphlet and answer any questions. Visits will ideally occur in person. If the mother is not at bedside, 1 attempt will be made to reach the mother by phone in which case the pamphlet will be forwarded by mail.
Study NCT05541536 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pamphlet
Description: Study team member will distribute pamphlet to beside nurse to give to mother. The pamphlet provides information about Learning Health Care (LHC) and clinical research.
Study NCT05541536 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Study participants will not receive the general information pamphlet or consultation.
Study NCT04572152 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AK119
Description: Subjects will receive AK119 by intravenous administration.
Study NCT04572152 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AK104
Description: On the same day subjects will receive AK104 by intravenous administration.
Study NCT04608903 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-sulforaphane 1%
Description: Administration of 4g L-sulforaphane per day, for 2 months
Study NCT04608903 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Group
Description: Administration of 4g corn starch colored with chlorophyll, per day, for 2 months
Study NCT05031741 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Peer Leader Model
Description: Teens will have an opportunity to interact with established peer leaders that are a part of the AccessKCTeen program. These leaders will receive a baseline training of their role, sexual and mental health. They will also receive health education and engage with a peer liason via text messages throughout the study.
Study NCT06772805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nemtabrutinib
Description: Oral Tablet
Study NCT06496672 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Modified long arm cast
Description: A shorter cast that frees the wrist
Study NCT06496672 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional long arm cast
Description: Current standard of care where the cast extends up to the palmar bar
Study NCT04881123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SER150
Description: Dosage Level(s): 30 mg (1 capsule of 15 mg twice a day - morning and evening) (except on Day 168 where participants will only receive a single dose (QD) in the morning)
Study NCT04881123 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dosage Level(s): Matched placebo (1 capsule twice a day - morning and evening) (except on Day 168 where participants will only receive a single dose (QD) in the morning)
Study NCT05274230 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Apollo Wearable
Description: Participants will be provided with the Apollo wearable device and asked to install the study mobile application on their mobile phone. Participants will use the Apollo for at least 30 minutes after waking up in the morning and at least 30 minutes before bed on the corresponding settings for those times of day. They will be given the Apollo Device TVS (10-200 Hz) to borrow which they will be instructed to wear everyday. They will be asked to continue to wear the device until all study data is collected.
Study NCT06309056 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VitalStim
Description: VitalStim is a device that provides neuromuscular electrical stimulation. It will be applied on muscles related to swallowing to stimulate muscle contraction.
Study NCT05654831 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo will be administered as oral tablet. Matching Placebo will be given orally during each dosing day.
Study NCT05654831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ECC5004
Description: ECC5004 will be administered as oral tablet(s) during each dosing day.
Study NCT04955561 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oxygen therapy
Description: Supplemental O2 at rest of 10 l/min for ten minutes followed by supplemental O2 at the prescribed exercise O2-flow rate during ESWT.
Study NCT04955561 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Air
Description: Supplemental O2 at rest of 10 l/min for ten minutes followed by medical Air at prescribed O2 flow rate during ESWT.
Study NCT04955561 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 10L/min O2
Description: Supplemental O2 at rest of 10 l/min for ten minutes followed by 10L/min O2 during ESWT.
Study NCT04642157 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ELIOS
Description: ELIOS is a suicide prevention system worldwide entirely tailored to the AYA contemporaneous modes of interaction on social media.~This includes~* A systematic initial contact with an ELIOS web-clinician~* Systematic recontacts by the ELIOS web-clinicians scheduled at 24h, 72h and/or 7 days, depending on the participants' level of suicide risk~* The opportunity to spontaneously contact the ELIOS system and get in contact with a web-clinician
Study NCT04642157 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: other resources contacts
Description: Three types of resources will be suggested via the ELIOS website:~* The General Practitioner (GP)~* The closest medico-psychologic center (CMP)~* The emergency services The order of presentation of the resource contacts will depend on the participants' intensity of suicidal ideation.
Study NCT06405464 — intervention group
Intervention type: DRUG
Intervention: VOCABRIA 30Mg Tablet
Description: CAB 30 mg Film-coated tablets
Study NCT06405464 — intervention group
Intervention type: DRUG
Intervention: EDURANT 25Mg Tablet
Description: RPV 25 mg film-coated tablets
Study NCT06405464 — intervention group
Intervention type: DRUG
Intervention: Cabotegravir Injectable Suspension
Description: CAB LA 600 mg prolonged release suspension for injection (3 mL)
Study NCT06405464 — intervention group
Intervention type: DRUG
Intervention: Rilpivirine Injectable Suspension
Description: RPV LA 900 mg prolonged release suspension for injection (3 mL)
Study NCT06405464 — intervention group
Intervention type: BIOLOGICAL
Intervention: Intact proviral DNA assay
Description: HIV-1 latent reservoir size
Study NCT06405464 — intervention group
Intervention type: BIOLOGICAL
Intervention: Full-length sequencing
Description: Proviral DNA
Study NCT06507163 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The post-surgical breathing exercise group
Description: Individuals in the Intervention-1 group were asked to perform 10 breathing exercises with IS every waking hour in addition to the routine practices of the clinic for 5 days in the postoperative period.
Study NCT06507163 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The pre- and post- surgical breathing exercise group
Description: Individuals in the Intervention-2 group were asked to perform 10 breathing exercises with IS every waking hour in addition to the routine practices of the clinic for a total of 10 days, 5 days in the preoperative period and 5 days in the postoperative period.
Study NCT05688787 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Perineural Injection
Description: .injections are done with a 27 gauge half 1/2 needle directed perpendicular to the skin and going~1/ to the skin surface delivering 1_2 cc of buffered 5% dextrose solution in the subcutaneous superficial perineural tissue we will be targeting the most triggering points for each patient emphasizing on pain located in thoraco-dorsal fascia, the fascia of the erectorspinae muscles along T10 to L2 dorsal rami, interspinoustenderness from medial branches of dorsal rami, superiorcluneal nerve at 7-8 cm from middle line cross the iliac crest\&amp; T10 cross over iliac crest at a distance 8-10cm
Study NCT05468073 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proleukin
Description: Sub-cutaneous injections of Interleukin-2 (PROLEUKIN ®) Induction phase: 5 consecutive days. A week break. Maintenance phase: once a week during 16 weeks
Study NCT05468073 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sub-cutaneous injections of placebo (NaCl) Induction phase: 5 consecutive days. A week break. Maintenance phase: once a week during 16 weeks.
Study NCT06095739 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: DA-OTC-002
Description: The topical formula of DA-OTC-002 was formed from 2 molecules: an alpha 1 agonist (synephrine) and a TAAR receptor agonist~A 1mL topical application of DA-OTC-002 was applied to a 10cm x 10xm target area of the right side of the scalp of each subject
Study NCT06071858 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Care Coordination
Description: * The study staff clinician will review all medical issues for each patient and reach out to primary care providers (PCP), dieticians, and other medical providers as needed.~* The study staff clinician will serve as point person for communication with emergency departments and inpatient providers if the patient requires those levels of care.~* The clinician will communicate with outside providers to provide background and ensure health decision making by those providers, visit and support patients as appropriate, access outside records and share with rest of the care team, and most critically ensure that a proper discharge plan has been made for the patient including care appointments, access to prescriptions and any new referrals made during hospitalization.
Study NCT06071858 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual Peer Support
Description: • Patients will be offered weekly 1:1 sessions with a Peer Provider as part of routine care in a mixture of in-person and virtual formats as appropriate to support patients around treatment decisions, and recovery.
Study NCT06071858 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital Outreach
Description: • mindLAMP smartphone application for various kinds of outreach including but not limited to medication and/or appointment reminders, resources, and activities such as breathing and meditation exercises.
Study NCT06071858 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Remediation
Description: * For participants identified as needing and/or wanting support around cognition.~* The cognitive remediation program is available online or in-app and offers memory, attention, processing speed, executive functioning, and social cognition training activities.
Study NCT06071858 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multi-Family Group Therapy
Description: * Families whose loved ones are in CSC clinic will be offered weekly group sessions with a study staff clinician.~* Each group may include 5-8 families and include a mixture of in-person and virtual formats.~* These groups will be open-ended, including psychoeducation, and practical problem-solving discussions around care and other topics.
Study NCT05241327 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Beetroot Juice
Description: Inorganic Nitrate
Study NCT05241327 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Beetroot Juice
Description: Inorganic Nitrate